Welcome to our dedicated page for Crown Reserve Acquisition I SEC filings (Ticker: CRACW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Crown Reserve Acquisition I's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Crown Reserve Acquisition I's regulatory disclosures and financial reporting.
Crown Reserve Acquisition Corp. I (CRAC) reports that it entered into a First Amendment to its Business Combination Agreement with CRAC Merger Sub Inc. and Carvix, Inc. on August 26, 2026. The amendment revises a covenant on shareholder approvals to align with the company’s Fourth Amended and Restated Memorandum and Articles of Association and clarifies that it does not change the voting rights of any security holder.
The amendment also clarifies that certain advisory organizational document proposals at the extraordinary general meeting are non-binding and not conditions to closing the business combination. In addition, it sets minimum annualized base salaries for specified Carvix executives in future employment agreements, tying bonus calculations to those base salary levels, while leaving the Carvix disclosure schedule otherwise unchanged. All other terms of the Business Combination Agreement remain in effect.
Highbridge Capital Management, LLC, a Delaware limited liability company and investment adviser, reported beneficial ownership of Class A ordinary shares of Crown Reserve Acquisition Corp. I.
Highbridge, on behalf of certain funds and accounts it advises, reported beneficial ownership of 1,637,592 Class A ordinary shares, representing 9.1% of this class. The percentage is based on 18,056,250 Class A ordinary shares outstanding as of May 14, 2026, as reported by Crown Reserve Acquisition Corp. I. Highbridge has sole voting and sole dispositive power over these shares, with no shared voting or dispositive power. The Highbridge Funds, including Highbridge Tactical Credit Master Fund, L.P., have the right to receive dividends and sale proceeds related to these securities.
Mizuho Financial Group, Inc., a Japan-based parent holding company, reports beneficial ownership of common shares of Crown Reserve Acquisition Corp. I. Mizuho and certain affiliates may be deemed to indirectly own 1,190,077 common shares, representing 6.6% of the class, held directly by its wholly owned subsidiary Mizuho Securities USA LLC. Mizuho reports sole voting and sole dispositive power over these shares, with no shared voting or dispositive power. The filing is certified by Managing Director Takahiro Katsura and indicates that the foreign regulatory scheme applicable to the parent holding company is represented as substantially comparable to that of functionally equivalent U.S. institutions.
Crown Reserve Acquisition Corp. I, a Cayman Islands SPAC, reported net income of $1,353,765 for the quarter and $1,090,272 for the six months ended June 30, 2026. Results were driven mainly by $1,548,367 and $3,073,108 of dividends on the IPO trust investments, partly offset by a $116,477 and $1,720,874 loss from remeasuring warrant liabilities and ongoing G&A and professional fees.
The IPO placed $172,500,000 into a U.S. Treasury-focused trust, which grew to $176,476,946 as of June 30, 2026, backing 17,250,000 redeemable Class A shares. The company has no cash outside the trust and a working capital deficit funded by its sponsor.
Crown Reserve signed a Business Combination Agreement with Carvix, Inc., under which Carvix stockholders will receive 50,000,001 shares at closing plus up to 50,000,100 earnout shares tied to EBITDA and revenue targets over four years; the sponsor may earn up to 3,000,000 additional shares. The SPAC must close a transaction by February 10, 2027 or liquidate. Management cites this deadline, lack of operating cash, and reliance on sponsor support as raising substantial doubt about its ability to continue as a going concern, and a previously identified material weakness in accounting for complex instruments remains unremediated.
W. R. Berkley Corporation, through its subsidiary Berkley Insurance Company, reports beneficial ownership of 1,217,433 Class A ordinary shares of Crown Reserve Acquisition Corp. I. This represents 6.7% of the Class A ordinary shares outstanding as of June 30, 2026.
All voting and dispositive authority over these shares is reported as shared, with no sole voting or dispositive power. The securities are identified as Class A ordinary shares, par value $0.0001 per share, CUSIP G2574F119.
Westchester Capital Management, LLC and Westchester Capital Partners, LLC report beneficial ownership stakes in Crown Reserve Acquisition Corp. I Class A ordinary shares. Westchester Capital Management beneficially owns 878,377 shares (5.09%) and Westchester Capital Partners beneficially owns 7,495 shares (0.04%).
The filing cites 17,250,000 Shares outstanding as of March 27, 2026 and notes that reported Ordinary Shares include Units, half-warrants exercisable at $11.50 and rights exercisable for 0.20 shares upon consummation of a Business Combination.
Crown Reserve Acquisition Corp. I entered a Business Combination Agreement with Carvix, Inc., under which Crown Reserve will domesticate from Cayman to Delaware and then merge a subsidiary into Carvix, leaving Carvix as a wholly owned subsidiary.
Carvix stockholders will receive an aggregate 50,000,001 shares of the post-combination company at closing, plus the right to earn up to an additional 50,000,100 shares over four fiscal years beginning January 1, 2027, based on EBITDA and revenue performance targets. The sponsor may also earn up to 3,000,000 shares over the first three years if specified milestones are met. Closing depends on stockholder approvals, SEC effectiveness of an S-4 registration statement, Nasdaq listing approval, antitrust clearance if required, minimum cash conditions and other customary requirements, with a potential outside date of September 30, 2026.